TL;DR

Flagship Pioneering, the US company behind Moderna, announced on 16 November that it is setting up its first company-creation lab outside the US, in London. Flagship Origination Lab, U.K. will start with £100 million to conceive, fund and build AI-native companies in health and other sciences. Founder Noubar Afeyan said the firm hopes partners will add a further £500 million, and it plans an initial team of about 50 scientist-entrepreneurs and operators.

What the lab will do

The new unit sits inside Flagship Labs, the group’s in-house innovation foundry, and will follow the model Flagship has used in Cambridge, Massachusetts: teams start from a scientific question and turn the answer into a company. Flagship says it has created more than 130 companies this way, and its ecosystem today includes Generate Biomedicines, Lila Sciences and Moderna.

The London lab will connect to Flagship business units worldwide, among them Pioneering Medicines and Pioneering Intelligence. The firm opened a London office and signed a memorandum of understanding with the UK government in 2023. Since then it has launched Quotient Therapeutics, which it calls its first transatlantic company, and its portfolio firms have run clinical trials in the UK.

Why the UK

Avak Kahvejian, president of Flagship Labs, said the UK was “a clear and deliberate choice”. He pointed to the country’s research strength, its trials infrastructure, its genomic and health datasets, and what he called an “agile regulatory environment”.

Science minister Chris McDonald said the UK was “a natural home for AI and life sciences companies” and that the new firms would carry British advances in both fields to global markets.

Looking Forward

Flagship’s reasons for choosing the UK echo a pitch ministers have been making; our report on McDonald’s comments about NHS data and AI pharma covered the government’s side of it. In our view, the test for the lab will be whether the companies it creates grow their operations in the UK. The £500 million partner target, which is an aim rather than a commitment, will also show how much co-investment the model attracts.